Frontier Tech Sectors
Life Sciences
George Freeman came to Parliament after 15 years in Cambridge’s biotech and venture capital sector. As Director of Early Stage Ventures at Merlin Biosciences and then chief executive of Amedis Pharmaceuticals, an early pioneer of using AI to predict the toxicity and metabolism of drug candidates, he saw first-hand how data could transform drug discovery. He went on to found 4D Biomedical, a translational medicine advisory business that brokered partnerships between universities, NHS hospitals and industry. Its work included helping to set up Scotland’s Translational Medicine Research Collaboration, a £50m partnership launched in 2006 between Wyeth, four Scottish universities and NHS Scotland, and working with King’s College London and the South London and Maudsley NHS Trust on using anonymised patient records for dementia research.
In 2011 David Cameron appointed him Government Adviser on Life Sciences. He helped shape the Strategy for UK Life Sciences, built on the principle of “every patient a research patient, every hospital a research hospital”. The strategy created the £180m Biomedical Catalyst for early-stage medical innovation, first proposed an early access scheme for breakthrough medicines and paved the way for the 100,000 Genomes Project. A champion of patients’ rights to their own data, he introduced the Electronic Patient Records (Continuity of Care) Bill in 2013 and co-founded the Patients4Data campaign, backed by more than 75 medical research charities. The Bill’s central measure, a single NHS number shared across health and social care, was taken up in the Health and Social Care (Safety and Quality) Act 2015 and became law in 2015.
In July 2014 he became the UK’s first Minister for Life Sciences, a post spanning the Department of Health and the business department. He commissioned the Accelerated Access Review to speed NHS patients’ access to innovative medicines, devices, diagnostics and digital tools. He also championed the Early Access to Medicines Scheme, which delivered its first medicine, the melanoma immunotherapy pembrolizumab, in 2015. Under his watch the 100,000 Genomes Project made its first diagnoses, the government announced the £150m UK Dementia Research Institute, and in 2016 he announced the relaunch of the Health and Social Care Information Centre as NHS Digital.
Background
Before entering Parliament, George spent over fifteen years in biomedical venture capital and technology investment, supporting the growth of innovative science and technology companies
Get in touch
For speaking engagements, advisory enquiries, media requests or any other questions, please contact George’s office.